The audit, which covered multiple active pharmaceutical ingredients (APIs), was conducted from 14 April to 18 April 2025.
The successful completion of the inspection reinforces Hikal’s compliance with international quality standards and strengthens its position in regulated markets like Brazil.
Hikal is engaged in the business of pharmaceuticals, crop protection, and specialty chemicals.
The company’s consolidated net profit rallied 48.08% to Rs 50.20 crore on 7.44% rise in revenue from operations to Rs 552.40 crore in Q4 FY25 over Q4 FY24.
Shares of Hikal rose 0.29% to Rs 377.10 on the BSE.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."